Antimicrobial stewardship (AMS) is the coordinated work of making sure every patient who needs an antimicrobial gets the right drug, at the right dose, by the right route and for the right duration, and that patients who do not need one do not get one. A hospital antimicrobial stewardship programme (ASP) turns that principle into daily practice, with a team, a set of interventions and the data to show they are working.
The stakes are rising. The GRAM study published in The Lancet in 2024 estimated that 4.71 million deaths in 2021 were associated with bacterial antimicrobial resistance, including 1.14 million directly attributable to it, and forecast 1.91 million attributable deaths a year by 2050 (GBD 2021 Antimicrobial Resistance Collaborators). In September 2024, world leaders at the UN General Assembly committed to cutting AMR deaths by 10% by 2030 and to a target that at least 70% of antibiotics used in human health come from the WHO Access group (WHO). Hospitals are where much of that progress has to happen.
Does antimicrobial stewardship work?
Yes, and the evidence is strong. A Cochrane review of 221 studies of hospital stewardship interventions found that they increased compliance with antibiotic policy from 43% to 58% and reduced the duration of antibiotic treatment by almost two days (1.95 days, from 11.0), with high-certainty evidence. Mortality was the same in both groups, at 11%, which shows antibiotic use can be reduced safely (Davey et al., 2017).
The core elements of a stewardship programme
The US CDC's Core Elements of Hospital Antibiotic Stewardship Programs describe seven building blocks. WHO's practical toolkit for AMS programmes in low- and middle-income countries and the ICMR's AMSP guidance in India follow the same logic.
- Leadership commitment: a written mandate, protected time for the team and a budget for data and IT.
- Accountability: a named physician lead, ideally with infectious diseases training, who is responsible for outcomes.
- Pharmacy expertise: a pharmacist co-lead who reviews prescriptions every day.
- Action: specific interventions that change prescribing (see below).
- Tracking: measuring antibiotic use, resistance and the programme's own processes.
- Reporting: regular feedback to prescribers, units and leadership.
- Education: ongoing training for doctors, pharmacists and nurses on resistance and optimal prescribing.
Who belongs on the AMS team
- Physician lead, usually an infectious diseases specialist or a senior intensivist.
- Clinical pharmacist, who runs day-to-day reviews.
- Clinical microbiologist, who owns the antibiogram, cascade reporting and diagnostic advice.
- Infection prevention and control (IPC) team, because every infection prevented is a course of antibiotics avoided.
- Unit champions in the ICU, surgery and emergency medicine, where prescribing volume is highest.
- Nursing and IT/data support, for time-outs, administration data and reporting.
Stewardship interventions that work
Preauthorisation of restricted antibiotics
Carbapenems, polymyxins and other Reserve or broad-spectrum Watch drugs need approval from the AMS team before, or soon after, the first dose. This is one of the fastest ways to change the use of high-risk agents.
Prospective audit and feedback
The AMS pharmacist or physician reviews active prescriptions and gives the prescriber specific advice, such as de-escalating, stopping, changing the dose or switching route. Unlike preauthorisation, it preserves prescriber autonomy and builds relationships.
48–72-hour antibiotic time-outs
Once culture results and the clinical picture are clearer, the treating team reassesses every empirical course and decides whether to continue, narrow, switch or stop it.
IV-to-oral switch and dose optimisation
Switch eligible patients to oral therapy as soon as they meet criteria, and adjust doses for renal function, weight and PK/PD targets, including therapeutic drug monitoring where available.
Shortest effective duration
For many common infections, shorter courses perform as well as longer ones. Facility guidelines should state default durations, and stop dates should be built into orders.
Local treatment guidelines based on your antibiogram
Empirical therapy should reflect your hospital's own resistance patterns, not a textbook. That depends on an up-to-date, unit-level antibiogram. See our guide to building a hospital antibiogram.
Diagnostic stewardship
Take cultures before the first antibiotic dose, avoid testing and treating asymptomatic bacteriuria, and use rapid diagnostics where they change management.
How to tell whether your programme is working
Track antimicrobial consumption (DDD and DOT per 1,000 patient days), your WHO AWaRe profile, process measures such as time-out completion and approval compliance, and outcomes such as C. difficile rates and resistance trends. We cover each one in detail in Antimicrobial Stewardship KPIs Every Programme Should Monitor.
Starting an AMS programme: a 90-day plan
- Weeks 1–2: mandate. Get a written commitment from the CEO or medical director, name the leads and agree reporting to the Hospital Infection Control Committee (HICC) or drugs and therapeutics committee.
- Weeks 3–6: baseline. Measure current consumption, run a point prevalence survey of antibiotic use and build or refresh your antibiogram.
- Weeks 6–8: focus. Choose two high-yield interventions, for example carbapenem preauthorisation and a 72-hour time-out in the ICU.
- Weeks 8–10: guidelines. Publish short, local empirical therapy guidance for the top five syndromes.
- Weeks 10–13: feedback loop. Report monthly by unit, celebrate wins and expand to the next area.
Why hospitals choose Ibhar
Most stewardship programmes stall on time and data, not on willingness. Ibhar gives AMS teams the visibility to act on every antibiotic course, and gives leadership the evidence that the programme is working. Ibhar is the infection intelligence platform for infection prevention and control (IPC), antimicrobial stewardship (AMS) and antimicrobial resistance (AMR). Hospitals from India to the Middle East use it, and it works alongside Epic, Oracle Health (Cerner) and InterSystems.
- 800+ hospitals with Ibhar implementation experience.
- 25 large hospitals in the AHPI and Pfizer antimicrobial stewardship programme.
- Peer-reviewed research in the American Journal of Infection Control and the Indian Journal of Medical Microbiology.
To see what Ibhar could do for your hospital, talk to our team.
Frequently asked questions
What is antimicrobial stewardship in simple terms?
It means using antibiotics and other antimicrobials only when they are needed, with the right drug, dose, route and duration, so they keep working for future patients.
Who leads an antimicrobial stewardship programme?
Usually a physician lead, often an infectious diseases specialist, working with a clinical pharmacist, a clinical microbiologist and the infection prevention and control team.
Is antimicrobial stewardship safe for patients?
Yes. A Cochrane review found that hospital stewardship interventions shortened antibiotic treatment by almost two days with no increase in mortality.